Navigation Links
Xenon Announces Appointment of VP, Discovery Research
Date:2/6/2008

VANCOUVER, Canada, Feb. 6 /PRNewswire/ -- Xenon Pharmaceuticals Inc., a drug discovery and development company, is pleased to announce today that it has appointed Charles J. Cohen as Vice President, Discovery Research.

"We are delighted to welcome Charlie to the Xenon team," commented Simon Pimstone, Xenon's President and CEO. "Charlie brings a unique combination of drug discovery experience and leadership including in areas that are highly relevant to Xenon such as pain. With a drug candidate for pain currently in clinical trials, and a backup compound expected to follow, we are certain that Charlie's background will be of great benefit to Xenon. In addition to his experience in the pain area, Charlie brings broad and diverse expertise which will be applicable to our multiple discovery and pre-clinical programs."

Dr. Cohen has spent the past approximately 25 years in the pharmaceutical/biotechnology industry with positions at Bayer Pharmaceuticals, Merck & Co and Vertex Pharmaceuticals. He held senior scientific positions and has published widely in the area of pain and more broadly in cellular neuroscience and neurology. Dr. Cohen received his PhD in Biophysics and Theoretical Biology from the University of Chicago.

About Xenon Pharmaceuticals Inc.

Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies focusing in the areas of Pain, Diabetes/Obesity, Anemia and Iron Overload. Xenon has partnerships with Novartis Pharma AG, Roche and Takeda Pharmaceutical Company Ltd. For more information, visit the Company's website at http://www.xenon-pharma.com.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.


'/>"/>
SOURCE Xenon Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
2. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
3. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
4. DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results
5. Physicians Reference Laboratory Announces New Diagnostic for Womens Health
6. CardioTech Announces Conference Call on February 12 at 2:30 PM Eastern for Third Quarter of Fiscal 2008
7. NeoStem Announces NY State License for Adult Stem Cell Collection
8. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
9. China-Biotics, Inc. Announces Rescheduling of Conference Call to Discuss Third Quarter 2008 Results
10. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
11. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... L3 ... to announce the company is now a certified iMedNet eClinical and Electronic Data ... enables the company’s clinical research team to build, customize and manage clinical trial ...
(Date:4/25/2017)... ... April 25, 2017 , ... Dr. ... Rehabilitation, P.A. , proudly announced today that acclaimed physiatrist Matthew Terzella, MD, has ... May 15, 2017. , Dr. Terzella completed his residency in Physical Medicine and ...
(Date:4/25/2017)... ... 2017 , ... Leaders of Quorum Review IRB and Kinetiq ... at this week’s Association of Clinical Research Professionals (ACRP) 2017 Meeting & Expo ... , "We are excited to present subject matter expertise on topics that impact the ...
(Date:4/24/2017)... Labs announced today the offer of whole genome sequencing (WGS) ... individuals have been able to access WGS at $1,000, this ... EUR 1,000. The sequencing includes bioinformatics analysis and ... informed decisions about disease monitoring, prevention, nutrition, exercise, health monitoring ... ...
Breaking Biology Technology:
(Date:4/19/2017)... , April 19, 2017 ... its vendor landscape is marked by the presence of ... is however held by five major players - 3M ... these companies accounted for nearly 61% of the global ... leading companies in the global military biometrics market boast ...
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
Breaking Biology News(10 mins):